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ABSTRACT 
The aim of this study was to evaluate safety and efficacy of oral hypoglycemic agents in obese Type-2 diabetic patients. The objectives are to 
compare fasting and postprandial blood sugar (PPBS) levels, to compare body mass index in all the groups and to i dentify glycosylated 
hemoglobin levels and adverse drug reaction in all the groups. Diabetes mellitus is one of the world’s major diseases. It currently affects an 
estimated143 million people worldwide and the number is growing rapidly. In the India, about 1-5% population suffer from diabetes or related 
complication. So there is need to cure this disease. Anti-diabetic drugs treat diabetes mellitus by lowering glucose levels in the blood. With the 
exceptions of insulin, exenatide, and pramlintide, all are administered orally and are thus also called oral hypoglycemic agents or oral anti 
hyperglycemic agents. There are different classes of anti-diabetic drugs, and their selection depends on the nature of the diabetes, age and 
situation of the person, as well as other factors. Diabetes mellitus type 1 is a disease caused by the lack of insulin. Insulin must be used in Type 
1, which must be injected or inhaled. Diabetes mellitus type 2 is a disease of insulin resistance by cells. Treatments include agents which 
increase the amount of insulin secreted by the pancreas, agents which increase the sensitivity of target organs to insulin , and agents which 
decrease the rate at which glucose is absorbed from the gastrointestinal tract. 
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INTRODUCTION 
Diabetes is a chronic progressive disorder, with multiple 
biological defects, which necessitates the use of a range of 
different classes of drugs in order to optimize disease 
control over the patients’ life span. To date there have been 
oral drug classes such as the biguanides, sulphonylureas, 
and injectable insulin options such as human and analogue 
insulin, which have become household names in the 
treatment of diabetes. New treatment options that target the 
incretin system are now available. These now widen the 
choices for commencing treatment for Type 2 diabetes. We 
can choose the appropriate drugs for optimal control of 
diabetes. 
We can choose the appropriate drugs for optimal control of 
diabetes targeting specific pathophysiological defects. It is 
important to understand the mechanism of action of these 
drugs to fully comprehend the mode and extent of glucose 
control that can be achieved as well as the side effects that 
could be anticipated.(1) 
Defective insulin secretion and insulin resistance appear 
very too early in obese patients, and both worsen equally as 
diabetes progresses. An increase in overall fat tissue, 
especially in visceral as well as ectopic fat depots, is 
particularly associated with insulin resistance. The 
relationship between obesity and diabetes is of such 
interdependence that the term “diabesity” has been coined. 
[2] The prevalence of diabetes for all age groups worldwide 
diabetes for all age groups worldwide was estimated to be 
2.8% in 2000 and it will be 4.4% in 2030. 
Diabetes affects approximately 200 million people 
worldwide, including more than a quarter of elderly living in 
developed countries. Diet and exercise are first line 
treatments along with oral hypoglycemic drugs to achieve 
the goal of improving glycogenic control and preventing 
both micro vascular and macro vascular complications. [3] 
   The term diabetes mellitus describes a metabolic disorder 
of multiple etiology characterized  by chronic hyper 
glycaemia with disturbances of carbohydrate, fat and protein 
metabolism resulting from defects in insulin secretion, 
insulin action, or both. The effects of diabetes mellitus 
include long–term damage, dysfunction and failure of 
various organs. Diabetes mellitus may present with 
characteristic symptoms such as thirst, polyuria, blurring of 
vision, and weight loss. In its most severe forms, 
ketoacidosis or a non– ketotic hyperosmolar state may 
develop and lead to stupor, command, in absence of effective 
treatment, death. Often symptoms are not severe, or may be 
absent, and consequently hyperglycemia sufficient to cause 
pathological and functional changes may be present for a 
long time before the diagnosis is made. 
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   As it is important to evaluate the benefits of hypoglycaemic 
agents in patients with various confounding risk factors, a 
comparative study is advantageous to choosing a right drug 
for the obese patient to reduce weight or put weight in 
control. The aim of this study was to evaluate safety and 
efficacy of oral hypoglycaemic agents in obese Type-2 
diabetic patients. The objectives are to compare fasting and 
postprandial blood sugar (PPBS) levels, to compare body 
mass index (BMI) in all the groups and to identify 
glycosylated haemoglobin. [4] 
Diabetes can cause serious health complications including 
heart disease, blindness, kidney failure, and lower-extremity 
amputations. Diabetes is the seventh leading cause of death 
in the United States.  
SYMPTOMS OF DIABETES 
People who think they might have diabetes must visit a 
physician for diagnosis. They might have SOME or NONE of 
the following symptoms: 
• Frequent urination  
• Excessive thirst 
• Unexplained weight los  
• Extreme hunger1 
• Sudden vision changes  
• Tingling or numbness in hands or feet 
• Feeling very tired much of the time  
• Very dry skin 
• Sores those are slow to heal  
• More infections than usual  
Nausea, vomiting, or stomach pains may accompany some of 
these symptoms in the abrupt onset of insulin-dependent 
diabetes, now called Type 1 diabetes. [5, 6] 
Pharmacotherapy 
Pharmacotherapy Oral antidiabetic (OAD) agents that will be 
discussed include: 
• Biguanides   
• Sulphonylureas  
•Non-sulphonylurea ( Meglitinides ) 
• Thiazolidinediones 
 • Alpha-glucosidase inhibitors 
 • Dipeptidyl peptidase IV (DPP-IV) inhibitors 
 • Glucagon-like peptide-1 (GLP-1) analogues 
• Biguanides: 
Biguanides are old agents that work by reducing hepatic 
glucose output and, to a lesser extent, enhancing insulin 
sensitivity in hepatic and peripheral tissues (ie, 
antihyperglycemics, hepatic insulin sensitizers). Phenformin 
was taken off the market in the United States in the 1970s 
because of its risk of causing lactic acidosis and the 
associated mortality (rate of approximately 50%). In 
contrast, metformin has proved effective and safe. [7, 8] It has 
been used in Europe for over thirty years, whereas in the 
United States it has been available since 1995. Metformin 
should be prescribed to all people with type 2 diabetes, 
unless contraindicated. Current recommendations of the 
American Diabetes Association (ADA) and European 
Association for the Study of Diabetes (EASD) include 
metformin, diet and exercise as first-line therapy for the 
treatment of patients with type 2 diabetes, irrespective of 
the presence of overweight status. [9] 
Mode of action 
Metformin has a variety of metabolic effects, No clinically 
significant drug interactions have been some of which may 
confer clinical benefits that reported. However, agents 
affecting gut motility can extend beyond glucose lowering. At 
the cellular level, met-crease the glucose- lowering effect of 
acarbose. Metformin improves insulin sensitivity to some 
extent, an action mediated via post-receptor signaling path-
3. Insulin Sensitizers ways for insulin. Recent data have 
suggested Insulin resistance is a prominent metabolic defect 
that adenosine 5′-monophosphate-activated protein. 
Kinase (AMPK) is a possible intracellular target of nant 
glucose-lowering mechanism of action of metmetformin.[10] 
Through phosphorylation of key pro- formin is to reduce 
excessive rates of hepatic glutens, AMPK acts as a regulator 
of glucose and lipid core production. Metformin reduces 
gluconeogene metabolism and cellular energy regulation.[11] 
Since sis by increasing hepatic sensitivity to insulin (figure 
metformin lowers blood glucose concentrations 4) and 
decreasing the hepatic extraction of certain without causing 
overt hypoglycemia it is most ap- gluconeogenic substrates 
(e.g. lactate). Hepatic propriately classed as an anti-
hyperglycemic – as glycogenolysis is also decreased by 
metformin. Indistinct from hypoglycemic – agent. The 
clinical sulin-stimulated glucose uptake in skeletal muscle is 
efficacy of metformin in patients with type 2 diabe- 
enhanced by metformin. This involves an increase tes 
requires the presence of insulin. The drug does in the 
movement of insulin-sensitive glucose transmit stimulate 
insulin release and a small decrease in porter molecules to 
the cell membrane; an increase fasting insulin 
concentrations is typically observed in the activity of the 
enzyme glycogen synthase in patients with 
hyperinsulinaemia. The predomi- promotes synthesis of 
glycogen. Metforminals Oral Antidiabetic Agents acts in an 
insulin-independent manner to suppress other class of oral 
antidiabetic agent or with insulin. Oxidation of fatty acids 
and to reduce triglyceride The drug is contraindicated in 
patients with imlevels in patients with 
hypertriglyceridaemia. paired renal function (i.e. serum 
creatinine This reduces the energy supply for hepatic gluco- 
>120–130 µmol/L, depending on lean body mass), 
neogenesis and has favourable effects on the glu- as a 
precaution against drug accumulation. Cardiac cose-fatty 
acid (Randle) cycle (in which fatty acids or respiratory 
insufficiency, or any other condition are held to compete 
with glucose as a cellular energy predisposing to hypoxia or 
reduced perfusion (e.g. source).[12] Glucose metabolism in 
the splanchnic hypotension, septicaemia) are further 
contraindicabed is increased by metformin through insulin-
indetions, as well as liver disease, alcohol abuse and a 
pendent mechanisms. This may contribute to the history of 
metabolic acidosis. Metformin can beblood glucose-lowering 
effect of the drug, and in used in the elderly, provided that 
renal insufficiencyturn may help to prevent gains in 
bodyweight. Coland other exclusions are not present. A 
difficulty inlectively, the cellular effects of metformin serve 
to practice is that significant renal dysfunction may 
becounter insulin resistance and to reduce the putative 
present without the aforementioned elevation of se-toxic 
metabolic effects of hyperglycaemia (glucose rum 
creatinine.toxicity) and fatty acids (lipotoxicity) in type 2 
diabetes. 
Side effects: 
1 Up to a third of patients on metformin experience 
gastrointestinal (GI) side effects, such as nausea, diarrhea, 
abdominal discomfort, and a metallic taste, which can be 
reduced by titrating the dose up slowly and by taking 
medication with or after meals? 
Kaur et al                                                                                                              Journal of Drug Delivery & Therapeutics. 2019; 9(3-s):770-777 
ISSN: 2250-1177                                                                                 [772]                                                                                      CODEN (USA): JDDTAO 
2 The reported incidence of lactic acidosis with metformin is 
rare at 0.03 per 1000 patient-years of use. It is fatal in 30% 
to 50% of cases.8 A recent systematic review found no cases 
of lactic acidosis associated with metformin use in Type 2 
diabetes when contraindications were observed.9 At high 
doses, especially in renal failure, it accumulates in 
mitochondria, inhibits oxidative phosphorylation and causes 
lactic acidosis (which can be further potentiated by alcohol). 
• Metformin can interfere with vitamin B12 absorption and 
may lower serum vitamin B12 levels through unknown 
mechanisms, but is rarely of clinical significance. Anemia has 
been observed in 7% of people in clinical trials. It appears to 
be rapidly reversible with discontinuation of the drug. It is 
recommended to monitor hematological parameters. [13] 
Contra-indications 
Metformin is contraindicated in people with the following 
risk factors for lactic acidosis: 
 Renal (serum creatinine ≥ 130 mmol/L in men, or ≥ 
120 mmol/L  in women) 
 Hepatic impairment  
 Respiratory insufficiency  
 Severe infection 
 Alcohol abuse 
 Heart failure requiring pharmacological therapy  
 Metformin should also be used with caution in elderly 
people (older than 80 years) with reduced lean body 
mass. It is recommended to monitor renal function 
upon initiating metformin and at least annually 
thereafter.10 
 Any patient undergoing radio-contrast studies 
should have metformin withheld one day before the 
study and 48 hours after the study to avoid any 
potential lactic acidosis. 
2 .Sulphonylurea secretagogues 
The sulphonylurea  group of drugs has been available for the 
last 50 years. All of them (glibenclamide, glipizide and 
gliclazide) have a similar mechanism of action that is 
mediated by inducing closure of the ATP-sensitive 
potassium (K+) channels. The intracellular retention of K+ 
changes the membrane potential resulting in depolarization 
of the ß-cell, and opening of the voltage-dependent calcium 
channels. This facilitates movement of Ca++ into the cell, 
stimulating exocytosis of insulin into the circulation. 
Traditionally, sulphonylureas are classified into first- and 
secondgeneration depending on their duration of action. The 
latter group, in general, has a greater potency and improved 
safety. 
Examples of the first-generation SUs include acetohexamide, 
tolbutamide and chlorpropamide. The latter drug has a long 
duration of action, up to 48 hours, and even its metabolites 
have active hypoglycaemic potential. 
Examples of the second-generation group include 
glibenclamide (Daonil®), glipizide (Minidiab®), and 
gliclazide (Diamicron®). Glimepiride (Amaryl®) is classified 
as a third-generation SU. 
All of them have a number of generics available, and most of 
the generics are of equal potency. All of them stimulate 
insulin release from pancreatic ß-cells that have residual 
function. They display, to some extent, a glucose-dependent 
effect, but still have a potential for serious hypoglycemia, 
which is especially a problem with chlorpropamide, 
especially in the context of skipped meals. Chlorpropamide 
use is thus best avoided. [14] 
Mechanism of Action  
SUs have a glucose independent mechanism of action, which 
means that they continue to exert their effects irrespective 
of ambient glucose concentrations in the circulation. They 
induce insulin release from beta cells by inhibiting ATP-
dependent potassium channels. Besides pancreatic beta 
cells, these channels are present in various tissues of the 
body including cardiomyocytes and vascular smooth muscle 
cells (SUR2 isoform). Modern SU such as glimepride act 
predominantly upon SUR 1 isoforms. 
SU also bind with an exchange protein called Epac 2, which 
interacts with Rap 1 protein to increase the number of 
insulin vehicles that fuse with beta-cell plasmalemma. This 
effect has been demonstrated for all SUs except gliclazide.
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Pharmacology 
Pharmacological properties of various SUs are detailed in Table-2.  
 
Table-2: Pharmacological properties of sulfonylureas. 
 
Non-sulphonylurea secretagogues (Meglitinides) 
These drugs, the so-called glinides, include repaglinide 
(NovoNorm®), a benzoic acid derivative, and nateglanide 
(Starlix®), a phenylalanine derivative. These agents are 
short-acting insulin secretagogues. Both have a similar action 
to SUs, acting on the same ß-cell receptors. They act on the 
ATP dependent potassium channels in pancreatic ß-cells, 
allowing opening of calcium channels and increased insulin 
release. 
They are differentiated from SUs by their much shorter half-
lives, and the absence in them of the sulphonic acid moiety, 
which allows them to be used where patients are allergic to 
sulphas. In view of their shorter duration of action, they have 
been used as ‘prandial drugs’, taken just before meals. Their 
rapid clearance reduces the potential for delayed 
hypoglycemia. 
As a general rule, the glucose lowering effect of 
sulphonylureas plateaus after half the maximum dose is 
reached. 
Pharmacology 
The meglitinides are non-sulfonylurea hypoglycemic agents 
that lower blood glucose levels by stimulating the release of 
insulin from the pancreas. Action of these agents is 
dependent on actively functioning beta cells in the pancreatic 
islets.   
The meglitinides bind to a non-sulfonylurea receptor on the 
pancreatic beta cell membrane. This leads to the closing of 
ATP-dependent potassium channels in the beta cell 
membrane and the opening of calcium channels. The 
resulting increased calcium influx induces insulin secretion. 
The ion channel mechanism is highly tissue-selective with 
low affinity for heart and skeletal muscle.  
Metformin (a component of Prandimet), is a biguanide-type 
hypoglycemic agent. It increases peripheral uptake and 
utilization of glucose, resulting in a reduction in hepatic 
gluconeogenesis, a reduction in glucose absorption from the 
gastrointestinal tract, and an improvement in insulin 
sensitivity of peripheral tissue. 
 
 
Pharmacokinetics  
 
Side effects 
In general, the SUs and non-SUs have similar side effects. 
Hypoglycaemia would tend to be more common in SUs with 
longer duration of action, for example with chlorpropamide 
rather than with the glinides. 
The most common adverse side effect is hypoglycaemia. The 
UKPDS reported an incidence of 1.2% in the SU-treated 
group.13 Hypoglycaemia is predisposed to by high doses, 
missed meals, excessive alcohol, and a history of renal or 
hepatic disease. 
Weight gain is the other significant side effect, and is usually 
seen in the context of improved glycaemic control. The 
average weight gain on a SU is some 2–5 kg. Less common 
side effects include GI disturbance, photosensitivity, 
abnormal liver enzymes, flushing (especially with 
chlorpropamide and alcohol), and chlorpropamide induced 
hyponatraemia, especially in patients on concomitant 
diuretic therapy.[15] 
Contraindications 
Nateglinide (Starlix) and repaglinide (Prandin) are 
contraindicated in patients with type 1 diabetes, diabetic 
ketoacidosis, or a known hypersensitivity to the drug or its 
inactive ingredients. Repaglinide (Prandin, Prandimet) is 
contraindicated in patients also taking gemfibrozil. [16] 
Any product containing metformin is contraindicated in 
patients with any of the following: renal disease or renal 
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dysfunction (serum creatinine > 1.5 mg/dL for males and > 
1.4 mg/dL for females), acute or chronic metabolic acidosis, 
including diabetic ketoacidosis, acute myocardial infarction, 
septicemia, pregnancy, or known hypersensitivity to 
metformin or other ingredients in the drug formulation. Due 
to the metformin component, the labeling for combination 
repaglinide/metformin (e.g., Prandimet) contains a boxed 
warning related to an increased risk of lactic acidosis, 
especially in patients with renal or hepatic impairment, 
sepsis, dehydration, excessive alcohol intake, or acute 
congestive heart failure. If lactic acidosis is suspected, 
combination repaglinide/metformin should be discontinued 
and the patient should be hospitalized immediately. Because 
metformin can cause vitamin B12 deficiency, patients being 
treated with any product containing metformin should have 
hematological parameters assessed annually. 
4. Thiazolidinediones 
Thiazolidinediones (TZD) are selective peroxisome 
proliferator activated receptor (PPAR) gamma agonists. 
PPARs in humans are associated with gene transcription. 
Activation of these receptors regulates the transcription of 
insulin responsive genes involved in the control of 
production, transport, and use of glucose. [17] 
The interactions of TZD result in an: 
 -Increased insulin-stimulated glucose uptake by peripheral 
tissues (skeletal muscle and adipose tissues) by improving 
insulin sensitivity 
-Reduced hepatic glucose production  
-Decreased lypolysis and  
-Enhanced adipocyte differentiation 
TZD currently available include pioglitazone (Actos®) and 
rosiglitazone (Avandia®). They can be prescribed as 
monotherapy or in combination with metformin or 
sulphonylureas. Its use with insulin is not recommended due 
to the excessive weight gain and fluid retention. [18] The 
weight gain may be mediated through a number of 
mechanisms:  
• It usually involves deposition of fat in the peripheral
 subcutaneous site with a reduction in visceral fat 
deposition.  
•  It could also be due to an increase in plasma volume (i.e. 
oedema) because of the activation of PPAR receptors in 
the kidneys.  
• The oedema may be due to a decrease in renal excretion 
of sodium and an increase in sodium and free water 
retention. 
Fluid retention and pedal oedema occurs in 3% to 5% of 
people taking TZD. This can precipitate congestive heart 
failure in patients with compromised cardiac function. 
Rosiglitazone and pioglitazone differ in their effects on 
lipids:  
• Rosiglitazone increases LDL-cholesterol (LDL-C) by 
0.34–0.47 mmol/L, has no effect on triglycerides (TG), 
and increases HDL-cholesterol (HDLC) by 0.05-0.09 
mmol/L. 
• Pioglitazone has a neutral effect on LDLC, decreases TG 
by 0.29–0.60 mmol/L, and increases HDL-C by 0.09-0.14 
mmol/ L.23 Both agents may reduce the level of small, 
dense LDL-cholesterol, which is thought to be the most 
atherogenic lipoprotein component in people with 
diabetes and may reduce macrovascular morbidity and 
mortality. 
Efficacy:  
Bennett et al reviewed RCTs comparing glitazones or 
thiazolidinediones (TZDs) (pioglitazone and rosiglitazone) 
and second-generation sulfonylureas (glibenclamide, 
glimepiride, and glyburide). The review found both 
treatments had similar effects on HbA1c.Five RCTs with up 
to 1 year or less in duration, compared glitazones and a SFU, 
showing greater weight gain with glitazones, favoring SFUs. 
Five RCTs compared rosiglitazone or pioglitazone with a 
SFU, indicating a greater increase in LDL with glitazones 
relative to a SFU. Eight RCTs compared rosiglitazone or 
pioglitazone with a SFU, indicating a favorable increase in 
HDL with glitazones relative to a SFU. Pioglitazone is favored 
for a greater decrease in TG over SFUs in 6 RCTs. However, 
when comparing rosiglitazone and SFUs, Bennett et al found 
conflicting evidence for benefits of TG lowering. In one RCT, 
while both rosiglitazone (at 8mg dose) and a SFU were 
associated with a decrease in TG, the differences were non-
significant; in another RCT a lower dose (4mg) of 
rosiglitazone lowered TG relative to a SFU, however, at a 
dose of 8mg, rosiglitazone increased TG relative to SFU with 
no statistical significance reported.The ADOPT study 
showed all-cause mortality and cardiovascular mortality to 
be similar for rosiglitazone and glyburide at 2.3% and 2.2%, 
respectively.As above, it should be noted that the FDA has 
placed a boxed warning for all thiazolidinedione agents, 
including rosiglitazone and pioglitazone for risk of 
congestive heart failure. 
Safety:  
Five RCTs determined a greater risk of mild to moderate 
hypoglycemia with SFUs over glitazones with an OR of 3.9. 
Although the ADOPT study with over 1300 participants in 
each arm reported no statistical significance for outcome of 
hypoglycemia between rosiglitazone and glyburide. Bennett 
et al reviewed 4 RCTs looking at outcome of CHF with 
glitazones versus SFU and found an increase of CHF 
incidence with glitazones over SFUs with an OR of 
1.68.While the review did not show statistical significance, 
clinical significance could not be ruled out.Three RCTs did 
not show a consistent difference in the occurrence of 
diarrhea between groups treated with pioglitazone or 
rosiglitazone and glyburide. 
5. α-Glucosidase Inhibitors  
α-Glucosidase inhibitors include acarbose and miglitol. They 
act on α-glucosidase, an enzyme found in brush border cells 
of small intestine, cleaving more complex carbohydrates into 
sugars. αGlucosidase inhibits the breakdown and absorption 
of carbohydrates (dextrins, maltose, sucrose and starch; no 
effect on glucose); their largest impact is on postprandial 
hyperglycemia and their effect on FPG levels is modest. They 
have been associated with a reduction in HbA1c by 0.7 to 1.0 
percent and FPG levels by 35 to 40 mg per dL (1.9 to 2.2 
mmol per L). These agents are thus most useful in patients 
who have mild FPG elevations or in patients with 
predominant postprandial hyperglycemia. However, the 
main side effects of α-glucosidase inhibitors are flatulence, 
abdominal discomfort, bloating and diarrhea, which reduce 
compliance in treated patients. As for metformin, patients 
should be instructed to take this medication with food, 
starting with the lowest effective dose and titrated slowly 
over intervals of two to four week. Although hypoglycemia is 
not typically associated with monotherapy with α-
glucosidase inhibitors, it can occur in combination with 
other drugs; it is important, to inform patients that the 
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traditional treatment for hypoglycemia may be blocked 
during treatment with α-glucosidase inhibitors and only 
glucose should be consumed in this condition. 
Mode of Action:   
 1. Acarbose blocks the digestion of starch, sucrose and 
maltose. The digestion of carbohydrate is delayed and occurs 
throughout the small intestine, rather than upper part of 
jejunum. Absorption of glucose and other monosaccharides 
in not affected. The net result is a decrease in post prandial 
rise in blood glucose. Most of the carbohydrate is eventually 
absorbed and that which is now absorbed is metabolised by 
the bacteria in the colon to short chain fatty acids which are 
then absorbed in the colon.    
2. Acarbose decreases meal stimulated secretion of gastric 
inhibitory polypeptide and other gastrointenstinal peptide 
(inhibitors) hormones. There is smaller increase in post 
prandial blood sugar level that leads to smaller increase in 
insulin level.   
3. Acarbose does not cause weight gain with the therapeutic 
doses.   
Efficacy:  
Van de Laar et al. and Bolen et al. reviewed 2 RCTs 
comparing submaximal dosed metformin and maximally 
dosed acarbose showing no significant differences in HbA1c 
reduction between the two treatment groups.No statistically 
significant differences were observed for weight reduction 
with either AGIs or metformin.Reviews by Van de Laar et al 
and Bolen et al, found no benefits to HDL or TG with either 
therapy.  One study, using submaximal doses of metformin 
and maximum doses of acarbose showed a reduction in LDL 
favoring acarbose. No evidence is available to determine all-
cause or CV mortality benefits with either treatment.  
Safety: 
 One RCT reported a low incidence of hypoglycemia risk with 
both agents, however, provided no statistical analysis. Van 
de Laar et al and Bolen et al reviews based on two trials, 
report higher rate of side effects for acarbose, favoring 
metformin. For total adverse events, one study reported an 
odds ratio of 1:5 in favor of metformin. Van de Laar et al 
reviewed one RCT comparing miglitol (AGI) and metformin, 
in which no statistically significant differences in GI adverse 
events were observed.Another study reports the incidence 
of withdrawal from the study due to GI adverse effects was 
58% for acarbose arm and 14.8% for metformin. 
6. Dipeptidyl peptidase IV (DPP-IV) inhibitors 
DPP-4, described in 1966 and also known as CD26 regarding 
its activity in immune system, is a 110 kDa plasma 
membrane-spanning cell surface glycoprotein ectopeptidase, 
ubiquitously expressed in tissues such as liver, lung, kidney, 
intestinal brush-border membranes, lymphocytes, and 
endothelial cells. DPP-4 rapidly degrades and inactivates 
GLP-1, GIP, and other peptides in vivo via cleavage of N-
terminal two amino acids. Inhibition of this enzyme leads to 
an increase in circulating endogenous GLP-1 and GIP levels; 
so that DPP-4 inhibitors are not incretin mimetics, but 
incretin enhancers. Unlike other GLP-1 based therapies, can 
be administered orally. Sitagliptin, vildagliptin and 
saxagliptin are DPP-IV inhibitors that are approved as initial 
pharmacologic therapy for the treatment of type 2 diabetes; 
as a second agent in those who do not respond to a single 
agent, such as a sulfonylurea, metformin or a 
thiazolidinedione; and as a third agent when dual therapy 
with metformin and a sulfonylurea does not provide 
adequate glycemic control. The usual dose of sitagliptin is 
100 mg once daily, with reduction to 50 mg for moderate to 
severe renal insufficiency (GFR <30 to 50 mL/min) and 25 
mg for severe renal insufficiency (<30 mL/min).The usual 
dose of saxagliptin is 2.5 or 5 mg once daily, with the 2.5 mg 
dose recommended for patients with moderate to severe 
chronic kidney disease (GFR ≤ 50 mL/min) and for patients 
taking strong cytochrome P450 3A4/5 inhibitors (e.g., 
ketoconazole). DPP-4 inhibitors mimic the therapeutic 
effects of incretin mimetics including stimulation of insulin 
secretion, inhibition of glucagon secretion, possibly 
preservation of β-cell mass and inhibition of apoptosis. 
These drugs display quite similar efficacy in lowering HbA1C 
(≤1% reduction) compared with other antihyperglycemic 
agents, but they are weight neutral and have a low potential 
for hypoglycaemia when used as monotherapy. One safety 
concern involves the potential of DPP-4 inhibitors to 
interfere with immune functions: a meta-analysis of pooled 
clinical trial data for sitagliptin and vildagliptin indicates an 
increased risk for infection (nasopharyngitis and urinary 
tract infection) and headache. Other adverse effects 
occurring with more frequency in sitagliptin—treated 
patients versus those receiving placebo include, back pain, 
osteoarthritis, and extremities pain  
Efficacy: 
 Bennett et al reviewed one 12-week moderately-sized 
double-blind RCT compared high dose sitagliptin with 
maximum dose glipizide and found similar reductions in 
HbA1c, -0.77% versus -1.00%, for DPP-4 inhibitor and SFU, 
respectively. Additional studies comparing DPP-4 inhibitor 
or SFU add-on therapy to metformin have shown similar 
results for reduction of HbA1c, not favoring either agent. 
Evidence indicates a benefit for weight reduction with a 
DPP-4 inhibitor over SFU, either as monotherapy and as 
combination therapy with metformin. However, due to lack 
of direct monotherapy comparative data, unable to 
determine true effect. Bennett et al review of lipid profile 
indicated an increase in LDL and HDL with sitagliptin over 
SFU, while the increase in TG with sitagliptin was less than 
the increase with SFU (3.6% versus 7.0%). However, in all 
lipid measures reviewers found an overlapping CI after 
placebo-subtracted change from baseline in each group. 
There is insufficient data to determine all-cause mortality 
benefits for this comparison.   
Safety: 
 Sitagliptin consistently has a better hypoglycemic profile 
compared to SFUs as monotherapy and as combination 
therapy with metformin. Additionally, reduced incidence of 
hypoglycemia with sitagliptin versus glipizide or glimepiride 
was observed during Ramadan in a multi-center study. This 
is a specialized patient population since observers of 
Ramadan abstain from food or water from dawn until dusk 
for the duration of the month of Ramadan. No differences in 
GI sideeffects have been observed with DPP-4 inhibitors and 
SFU as monotherapy or combination therapy. 
• Glucagon-like peptide-1 (GLP-1) analogues 
Glucagon-like peptide-1 (GLP-1) analogues are one of the 
more recent additions to the type 2 diabetes 
armamentarium and work by mimicking the incretin system 
to lower glucose and increase insulin. The drug class also 
exerts associated non-glycaemic advantages, such as weight 
loss. The first GLP-1 analogue was approved for use in 
Australia in 2007 and has been subsidised by the 
Pharmaceutical Benefits Scheme since 2008, yet its use 
remains relatively low. This article discusses the mode of 
action of GLP-1 analogues, their use in Australia and how to 
use and initiate GLP-1 analogues in people with type 2 
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diabetes, using case studies.Benefits Scheme since 2008, yet 
its use remains relatively low. This article discusses the 
mode of action of GLP-1 analogues, their use in Australia and 
how to use and initiate GLP-1 analogues in people with type 
2 diabetes, using case studies. 
Pharmacological Effects of GLP-1 
GLP-1 has a number of potentially beneficial effects in the 
setting of type 2 diabetes. Intravenous administration of 
exogenous GLP-1 to patients with type 2 diabetes was 
shown to reduce plasma glucose concentrations to the 
normal fasting range, even in patients who had an 
inadequate response to oral antihyperglycemic drugs. The 
effects of exogenous GLP-1 observed after administration to 
patients with type 2 diabetes include: 
 Decreased glucagon concentrations 
 Improved insulin sensitivity 
 Decreased A1C 
 Slowed gastric emptying 
 Increased satiety 
 Decreased free fatty acid concentrations 
 Decreased body weight 
 
 
Actions of GLP-1 in target tissues. Adapted with permission GI, gastrointestinal. 
 
Use in Combination Therapy 
As dual therapy, GLP-1 receptor agonists are recommended 
in combination with metformin for patients who do not 
achieve A1C goals with metformin alone. For patients 
requiring triple therapy, GLP-1 receptor agonists can be 
combined with metformin and a sodium–glucose 
cotransporter 2 inhibitor in patients with persistent 
hyperglycemia. This triple combination is particularly well 
suited for overweight patients trying to control their weight. 
Additionally, incretin use with basal insulin may delay the 
use of bolus (mealtime) insulin with reduced risk of 
hypoglycemia. This simplified regimen reduces the need for 
matching mealtime insulin to specific carbohydrate ratios 
and also helps mitigate the weight gain often seen with 
insulin use. [19] 
DISCUSSION 
The first line of treatment is lifestyle modifications and 
metformin. If metformin alone cannot achieve a good 
glycemic control or it is not tolerated or is contraindicated, a 
second drug selected among the sulfonylureas, 
thiazolinediones, incretin mimetics and incretin enhancer 
drugs must be used. What is particularly relevant, anyway, is 
to avoid therapeutic inertia, thus therapy should be modified 
as soo+n as possible to keep glycemic control HbA1c at about 
7%. In this second step, various factors such risk of 
hypoglycemia, comorbidities, age of patients, and presence of 
diabetic complications and cost of treatment must be 
properly considered to individualize treatment 
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